Rochester, N.Y. — A trailblazing new study suggests a new way to effectively treat certain types of cancer. Research conducted at the Wilmot Cancer Institute shows immunotherapy to be highly effective ...

ROCHESTER, N.Y. (WROC) — A groundbreaking Hodgkin lymphoma study from the University of Rochester Medical Center showed a 92% survival rate with fewer side effects and reduced radiation therapy use.

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Cell identity crisis: Researchers found Hodgkin lymphoma cells are B cells stuck mid-change into plasma cells, unable to produce antibodies, reframing its origin. Why early matters: Five-year survival ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

—In a recent study, French survivors of non-Hodgkin lymphoma (NHL) reported significant physical impairments, emotional distress, and relationship issues, raising new questions about their future care ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial. The regimen, ...

What is it: Hodgkin lymphoma is a less common type of lymphoma that often starts in the upper body and is marked by the presence of Reed‑Sternberg cells. Treatment outlook: With modern therapies, ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a ...